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ABSTRACT: Background: Isolated rapid eye
movement sleep behavior disorder is known to be
prodromal for alpha-synucleinopathies, such as
Parkinson’s disease (PD) and dementia with Lewy
bodies. The [18F]fluorodeoxyglucose-positron emis-
sion tomography (PET)–based PD-related brain pat-
tern can be used to monitor disease progression.
Objective: We longitudinally investigated PD-related
brain pattern expression changes in 20 subjects with
isolated rapid eye movement sleep behavior disorder
to investigate whether this may be a suitable tech-
nique to study prodromal PD progression in these
patients and to identify potential phenoconverters.
Methods: Subjects underwent two [18F]
fluorodeoxyglucose-PET brain scans 3.7 years
apart, along with baseline and repeated motor, cogni-
tive, and olfactory testing within roughly the same
time frame.
Results: At baseline, 8 of 20 (40%) subjects signifi-
cantly expressed the PD-related brain pattern (with z
scores above the receiver operating characteristic–
determined threshold). At follow-up, six additional
subjects exhibited significant PD-related brain pattern
expression (70% in total). PD-related brain pattern
expression increased in all subjects (P = 0.00008).
Four subjects (20%), all with significant baseline PD-
related brain pattern expression, phenoconverted to
clinical PD.
Conclusions: Suprathreshold PD-related brain pattern
expression and greater score rate of change may sig-
nify greater shorter-term risk for phenoconversion.
Our results support the use of serial PD-related brain
pattern expression measurements as a prodromal PD
progression biomarker in patients with isolated rapid
eye movement sleep behavior disorder. © 2020 The
Authors. Movement Disorders published by Wiley
Periodicals LLC. on behalf of International Parkinson
and Movement Disorder Society.
Key Words: [18F]FDG-PET; rapid eye movement
sleep behavior disorder; Parkinson’s disease–related
pattern; neuroimaging; prodromal progression
biomarker
Isolated or idiopathic rapid eye movement sleep
behavior disorder (iRBD) is known to be prodromal for
alpha-synucleinopathies, such as Parkinson’s disease
(PD), dementia with Lewy bodies (DLB), or more
rarely, multiple system atrophy (MSA) in >80% of
cases.1–3 As such, patients with iRBD are critical for the
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study of prodromal PD development and will likely be
key to disease-modifying drug trials.
However, this necessitates the availability of
reliable biomarkers for the tracking and prediction of
disease progression and phenoconversion to manifest
alpha-synucleinopathies. Equally important, these bio-
markers must be able to identify those who will not
phenoconvert.
Accordingly, this study focuses on the longitudinal
change in expression of a characteristic pattern of [18F]
fluorodeoxyglucose positron emission tomography
([18F]FDG-PET)-based abnormal cerebral glucose
metabolism known as the “PD-related pattern” (PDRP)
in subjects with iRBD. The PDRP is defined by the
Scaled Subprofile Model Principal Component Analysis
(SSM/PCA) method,4,5 and it has been widely used in
the study of parkinsonian syndromes.6 Previous reports
have demonstrated that PDRP expression precedes
onset of motor symptoms by several years in prodromal
patients,7–9 and that in manifest PD, pattern expression
increases with disease progression10 and decreases with
effective symptomatic treatment.11
Repeated longitudinal measurements of [18F]FDG-
PET-based disease-related metabolic brain pattern
expression in patients with iRBD have not been per-
formed before. We therefore studied 20 subjects with
iRBD with glucose metabolic brain imaging, as well as
motor, cognitive, and olfactory testing two times
approximately 4 years apart. Our primary purpose was
to investigate whether serial PDRP expression measure-
ments may be a suitable technique to study prodromal
PD progression in patients with iRBD.
Methods
Study Design and Participants
This prospective, two-part longitudinal pilot study
took place at the University Medical Center of Gro-
ningen in Groningen, the Netherlands, and at the
Philipps-Universität Marburg in Marburg, Germany.
Study protocols for the baseline and follow-up investi-
gations were approved by the institutional review
boards of both institutions, and voluntary informed
consent was obtained from each subject at baseline and
follow-up after verbal and written explanation of the
study, in accordance with the Declaration of Helsinki.
Twenty subjects with iRBD (3 Dutch and 17 German)
were evaluated with baseline and follow-up [18F]FDG-
PET imaging, as well as motor, cognitive, and olfactory
testing (see Table 1 for demographics). At baseline, sub-
jects with iRBD with a clinical diagnosis of parkinson-
ism, dementia, or history of psychotropic medication
use before or during iRBD onset were excluded.
In addition, 16 age- and gender-matched healthy
control subjects (HCs) (13 male/3 female, age
63.1 ± 6.7 years) underwent baseline [18F]FDG-PET
imaging to z-transform the iRBD PDRP scores.
Exclusion criteria for all subjects at baseline included
a history of (other) neurological diseases, diabetes
mellitus, hyperthyroidism or hypothyroidism, stroke,
significant head trauma, or other relevant
comorbidities.
At both centers, phenoconversion to PD or DLB was
determined by the neurologist performing the motor
examination, according to the UK Parkinson’s Disease
Society Brain Bank diagnostic criteria or the DLB
Consortium consensus criteria.12,13 In addition, at
Philipps-Universität Marburg, a neurologist confirmed
the presence of PD/DLB twice, 3 months apart, in phen-
oconverted German subjects.
[18F]FDG-PET
Twenty RBD Screening Questionnaire–screened and
video polysomnographically confirmed iRBD patients
underwent baseline and follow-up [18F]FDG-PET imaging
an average of 3.7 ± 0.6 years apart. Sixteen HCs under-
went baseline [18F]FDG-PET imaging as well. All baseline
and follow-up scans were performed on a Siemens Bio-
graph mCT64 or mCT40 PET/CT camera (Siemens,
Munich, Germany) at the University Medical Center of
Groningen. Images were reconstructed with OSEM3D
(3 iterations, 21 subsets), time-of-flight, point-spread-func-
tion, Gaussian 8-mm full-width-at-half-maximum spatial
filter, and matrix size 256 (corresponding to a voxel size
of 2 mm × 3.18 mm × 3.18 mm).
Central nervous system depressants and any iRBD-
related medications (ie, melatonin or clonazepam) were
discontinued in all HCs and subjects with iRBD for at
least 24 hours before baseline and follow-up imaging.
All iRBD and HC images were spatially normalized
to an [18F]FDG-PET template in Montreal Neurological
Institute brain space14 using SPM12 software
(Wellcome Centre for Human Neuroimaging, London,
UK) implemented in MATLAB (version R2019a;
MathWorks, Natick, MA, USA).
A PDRP based on 16 HCs and 14 patients with PD
was defined with the SSM/PCA4 method using data pre-
pared to the same specifications as the earlier iRBD and
HC data (see Supporting Information Fig. S1) (notably,
these 16 HCs are a separate cohort from the one
described earlier).
PDRP expression in subjects with iRBD and HCs was
calculated using in-house code. PDRP subject scores
were z-transformed to HCs such that the mean HC
PDRP z score was 0, with a standard deviation of ±1.
A receiver operating characteristic (ROC) analysis was
performed to best differentiate between HCs and
patients with PD, which determined a z score cutoff of
1.98 (specificity 100%, sensitivity 85.7%; high specific-
ity will be an important consideration for drug trials to
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take into account to minimize misclassification of
nonphenoconverters).
A Hoffman 3D Brain Phantom allowed for linear
correction of raw PDRP score offsets between the
mCT40 and mCT64 scanners (see Supporting
Information).
Motor, Cognitive, and Olfactory Assessment
All 20 subjects with iRBD were additionally assessed
using the Unified Parkinson’s Disease Rating Scale, Part
III (UPDRS-III; motor examination),15,16 the Montreal
Cognitive Assessment (MoCA),17 and the Sniffin’ Sticks
16-item olfactory odor identification test18 at baseline
and follow-up. A 5-point change in the UPDRS-III was
considered to be clinically significant.19 MoCA scores
≤25 out of 30, and Sniffin’ Sticks identification score
≤10 out of 16 were considered to be pathological.17,18
Statistical Analysis
Variables were tested for normality of distribution
with the Shapiro-Wilk test, and PDRP z scores and
age were subsequently considered to be distributed
parametrically.7
The rest of the variables (UPDRS-III, MoCA, and
olfactory scores; years duration of iRBD; and variables’
rates of change) were considered to be non-
parametrically distributed. Correlations between these
and PDRP z scores were compared with a two-sided
Spearman rank correlation coefficient.
A one-sample Wilcoxon signed rank test was used to
examine PDRP z score change per year, UPDRS-III
score change per year, MoCA score change per year,
and olfactory score change per year. A Spearman rank
correlation coefficient was used to compare PDRP
z score change per year with UPDRS-III score change
per year, MoCA score change per year, and olfactory
score change per year.
These analyses were not corrected for multiple com-
parisons. Correlations were considered to be significant
at P < 0.05 (uncorrected). All analyses were performed
using SPSS v.24 (SPSS Inc., Chicago, IL).
Due to small subgroup sizes, we did not run statisti-
cal analyses based on phenoconversion status. Instead,
these results are described qualitatively.
This study is registered with the Netherlands Trial
Register, number NL8057.
Results
Between 2014 and 2015, 20 patients with iRBD
underwent baseline [18F]FDG-PET imaging, as well as
motor, cognitive, and olfactory testing (see Table 1).
At baseline, 8 of 20 (40%) subjects with iRBD
expressed a PDRP z score above the ROC-determined
threshold of 1.98. At follow-up, six additional subjects
with iRBD exhibited suprathreshold PDRP z scores, for
a total of 14 of 20 (70%). PDRP expression increased
among all 20 (100%) subjects between baseline and
follow-up (see Fig. 1). At the group level, PDRP expres-
sion was significantly higher at follow-up than at base-
line (Wilcoxon P = 0.00008). The average absolute
z score increase was by 2.1 ± 1.1 points, with an aver-
age z score increase of 0.6 ± 0.3 point per year.
UPDRS-III, MoCA, and olfactory scores did not
change significantly between baseline and follow-up
testing (Wilcoxon P < 0.33, 0.48, and 0.26, respec-
tively). However, olfactory scores correlated signifi-
cantly with PDRP z scores at baseline and follow-up
(Spearman P < 0.0005 and P = 0.001, respectively; see
Supporting Information Fig. S2), although olfactory
score change per year did not correlate to PDRP scores
or PDRP change per year. UPDRS motor scores corre-
lated with PDRP z scores at follow-up, but not at base-
line (Spearman P = 0.017 vs. 0.099). In addition,
UPDRS-III score change per year did correlate signifi-
cantly with PDRP z score change per year (Spearman
P = 0.024; see Supporting Information Fig. S3). MoCA
scores and MoCA change per year did not correlate to
PDRP z scores or PDRP change per year. In fact, all
follow-up MoCA scores were within the normal range
except for one (25), which was from a phenoconverted
FIG 1. PDRP expression changes between baseline and follow-up [18F]
FDG-PET imaging. Burgundy lines denote phenoconverted subjects;
diamonds denote point of clinical phenoconversion.
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subject with the highest PDRP z score of the entire
iRBD cohort (9.11).
No significant correlation was found between age of
iRBD onset, age or duration of iRBD at time of follow-
up, and any other variable tested in this study.
All four phenoconverters had suprathreshold baseline
and follow-up PDRP z scores, as well as greater PDRP
score rate of change (see Fig. 1).
Discussion
For the first time, this follow-up study of serial [18F]
FDG-PET imaging demonstrates that the expression of
abnormal cerebral metabolism in patients with iRBD
increases over time. Our results support the use of serial
[18F]FDG-PET imaging and PDRP expression measure-
ments as a prodromal disease progression biomarker in
patients with iRBD. Previous cross-sectional findings
demonstrated that abnormal metabolic expression in
iRBD can begin years before motor manifestations of
alpha-synucleinopathies.7
Motor, cognitive, and olfactory scores did not change
significantly between baseline and follow-up. This may
be attributable to bias because of the test-retest effect
(with the MoCA) or guessing (in the case of the olfac-
tion test).20 Olfaction has previously been reported not
to be a disease progression biomarker in iRBD.21 In
contrast, [18F]FDG-PET showed consistent, significant
changes between baseline and follow-up imaging,
which corresponded to changes in motor function.
Based on the four phenoconverted subjects, we infer
that subjects with suprathreshold absolute PDRP
expressions and higher PDRP rates of change may be at
shorter-term risk for phenoconversion to clinical alpha-
synucleinopathy. This study underscores the impor-
tance of repeated PDRP measurements for its imple-
mentation as a disease progression biomarker.
One of the strengths of this study includes its longitu-
dinal nature. Some of the limitations of this study
include small sample size and lack of repeat measure-
ments of the HC cohort for comparison. Investigation
of greater numbers of subjects with iRBD will be neces-
sary to confirm or modify the conclusions of this study.
In addition, a separate investigation into expressions of
the DLB- or MSA-related patterns in this cohort was
beyond the scope of this report.6,22
Further longitudinal studies should also examine the
relationship between [18F]FDG-PET and other bio-
markers, such as dopamine transporter imaging with
[123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-
(4-iodophenyl)nortropane single-photon emission com-
puted tomography ([123I]FP-CIT-SPECT).23,24 The lat-
ter is a well-studied potential prodromal progression
biomarker in alpha-synucleinopathies. However, serial
[18F]FDG-PET imaging may have an advantage,
because [18F]FDG-PET allows for quantitative analysis
of changes in glucose uptake in all areas of the brain at
once, whereas [123I]FP-CIT-SPECT is predominately
used to visualize the dopaminergic nigrostriatal tract.
[18F]FDG-PET also likely has greater potential to iden-
tify which specific parkinsonian disorder will develop in
a patient with iRBD.6,22 In addition, it is known that
some patients with DLB may have initially negative
[123I]FP-CIT-SPECT scans.25
One hundred subjects with iRBD are currently being
recruited for ongoing multicenter, multinational
research within the scope of this project to validate our
findings.
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